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Abstract 
CYP2E1 is an important cytochrome P450 isoform in many endogenous processes and in the 
metabolism of organic solvents, a number of drugs and pre-carcinogens. Information on the 
abundance of the enzyme may be valuable in various types of research in the field of toxicology and 
pharmacology. An indirect ELISA for the quantification of CYP2E1 in human liver microsomes was 
developed and successfully validated. All samples, including validation samples and calibrators, were 
diluted to a final concentration of microsomal protein of 10 µg/ml. Detection of the antigen was 
obtained through binding of a polyclonal antibody raised against the full length protein, followed by 
the addition of horseradish peroxidase conjugated secondary antibodies and enzymatic detection. A 
five-parameter logistics function with 1/x weighting was used for quantification within the 
concentration range of 4-256 pmol CYP2E1/mg microsomal protein. The method showed acceptable 
intra- and inter-assay precision, with calculated coefficients of variation of 6.3-15.2% and 11.3-21.0%, 
respectively. The relative error varied between -2.3 and 8.9%, and the total error between 16.0 and 
27.2%. No significant cross reactivity with other abundant CYP isoforms was observed. The method 
was evaluated through the analysis of samples from a pharmacokinetic study, and the comparison 
with the CYP2E1 activity in those samples.  
 
KEYWORDS:  
Cytochrome P450; drug metabolism; human liver microsomes; Enzyme linked immunosorbent assay; 
validation 
1. Introduction 
Cytochrome P450 (CYP) enzymes are key enzymes in the metabolism of many endogenous 
compounds and numerous xenobiotics. One member of the CYP superfamily is the isoform CYP2E1, 
which has broad substrate specificity. Besides being the main enzyme in the biotransformation of 
organic solvents, it also metabolizes certain drugs and pre-carcinogens. CYP2E1 is reasonably 
conserved between mammalian species, probably due to its important endogenous role [1]. The 
enzyme is highly inducible by alcohol, and many of its substrates often are also inducers. Due to its 
important function in the biotransformation of xenobiotics, information on CYP2E1 may be needed in 
various types of studies in the fields of, amongst others, toxicology and pharmacokinetics. Changes in 
the enzyme in specific situations may occur on the level of mRNA expression, protein expression or 
enzyme activity. For example, Liddle et al investigated the effects of growth hormone on the mRNA 
expression, the protein level and the activity of CYP3A4 [2]. They observed a similar change in all 
three measures, and thus suggested that the changes occurred at a pretranslational level. The same 
factors were evaluated by George et al in patients with cirrhosis [3, 4]. For some isoforms (CYP1A2, 
3A, and 2C), a good correlation was observed between the three measures, indicating 
pretranslational alterations in liver diseases. For CYP2E1 however, there was no strong correlation 
between the mRNA and protein levels, suggesting both pre- and posttranslational effects of the 
disease. These examples show the importance of abundance measurements in the characterization 
of enzymes in a specific situation. 
The CYP enzymes are mainly located in the liver and 96% of these enzymes are present in the 
subcellular fraction called microsomes [5]. Microsomes are easy to prepare and have an excellent 
long term stability [6, 7]. Therefore, they are a good choice to perform abundance measurements. 
About 10% of the total CYP content of the liver consists of CYP2E1 [1, 8]. In adults, an average 
abundance of 50 pmol CYP2E1/mg microsomal protein was detected. Several techniques can be used 
to determine CYP abundance. Western blotting is the most widely used technique, but it has some 
disadvantages, such as the time consuming process and the susceptibility to technical difficulties. 
Moreover, it provides only semi-quantitative data. In order to overcome these disadvantages, 
Snawder et al developed an indirect ELISA for the quantification of several CYPs in rat liver 
microsomes [8]. This method has a higher throughput and is easier to perform than a western blot. 
However, the described method is applied to rat samples, not to human samples, and a primary 
antibody raised against only a part of the protein is used. Consequently, some proteins may be 
missed during analysis, as it is unpredictable which part of the protein is available for antigen-
antibody interaction after adsorption of the microsomally embedded antigen to the microplate. 
In this article, we report the development and validation of an indirect enzyme-linked 
immunosorbent assay for the quantification of CYP2E1 in human liver microsomes, using a polyclonal 
primary antibody raised against the full length protein.   
2. Materials and methods 
2.1. Chemicals 
Tween 20®, sodium chloride, potassium chloride, and sodium carbonate and bicarbonate were 
purchased from VWR (Leuven, Belgium), hydrochloric acid from Acros Organics (Geel, Belgium), and 
tris(hydroxy-methyl)aminomethane, and chlorzoxazone from Sigma-Aldrich (Buchs, Switzerland). 
NADPH was obtained from Biopredic International (Rennes, France). All other chemicals were at least 
reagent grade.  
2.2. Recombinant CYP enzymes 
Microsomes prepared from insect cells infected with a virus engineered to express human CYP2E1 
were used (2000 pmol rCYP2E1/ml, 8.4 mg microsomal protein/ml, BD Supersomes™, BD Gentest, 
Franklin Lakes, USA) to prepare calibrators and validation samples. Corresponding Control 
Supersomes™ (BD Gentest), i.e. microsomes prepared from the same type of insect cells but without 
expression of human CYP2E1, were used as negative controls (blanks) for the analysis. The final 
composition and concentrations of the calibrators were 256, 128, 64, 32, 16, 8, 4 and 2 pmol 
rCYP2E1/mg protein in a pH 9.4 carbonate-bicarbonate plating buffer. A final concentration of total 
microsomal protein of 10 µg/ml was obtained by adding Control Supersomes™, if necessary. The 
validation samples (VS), with final concentrations of 4, 10, 50, 130 and 256 pmol rCYP2E1/mg 
protein, were prepared similarly. For the cross-reactivity experiments, the Supermix Supersomes™ of 
BD Gentest were used. These were prepared from the same type of insect cells as described above, 
but which expressed human CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. 
2.3. Determination of CYP2E1 in human microsomes 
Prior to plating one µg of microsomal protein/well in a black 96-well MaxiSorp® micro-titer plate 
(Nunc, Roskilde, Denmark), the microsomal samples were diluted to a concentration of 10 µg of 
microsomal protein/ml using a carbonate-bicarbonate buffer pH 9.4. Plates were incubated 
overnight at 4°C, after which the plating solution was removed. Subsequently, plates were washed 3 
times by adding 300 µl wash buffer (Tris-buffered saline (TBS) with 0.05% (v/v) Tween 20®, pH 7.2), 
soaking during 2.5 min and aspiration of the buffer. Three hundred µl of StartingBlock™ blocking 
buffer in TBS with Tween 20® (Thermo Scientific, Rockford, USA) was added as a blocking agent, and 
plates were incubated for 1h at room temperature (±23°C). After aspiration of the blocking buffer, 
plates were washed 3 times as described previously. The primary antibody, i.e. a polyclonal antibody 
raised in rabbit against the full-length human CYP2E1 protein (MaxPab® antibody, Abnova, Taiwan), 
was diluted in blocking buffer (1:1600). Hundred µl was added to each well, followed by incubation 
of the plates for 1h at 37°C. Primary antibody was removed and plates were washed as described 
above. Subsequently, 100 µl of secondary antibody dilution in blocking buffer (1:10000; goat anti-
rabbit IgG conjugated with horse radish peroxidase (HRP) from Thermo Scientific (Rockford, USA)) 
was added and plates were incubated at for 1 h at 37°C. Unbound secondary antibody was removed, 
plates were washed, and 100 µl of premixed HRP substrate (QuantaBlu™ Fluorogenic peroxidase 
substrate and peroxide, Thermo Scientific, Rockford, USA) was added to each well. The reaction was 
stopped after 60 min at 37°C with the stop solution from the QuantaBlu™ kit, and fluorescence was 
determined at an excitation wavelength of 320 nm, and emission at 405 nm (Ascent Fluoroscan, 
Thermo Scientific, Rockford, USA). Curve fitting and data analysis was performed using the 
Masterplex® Readerfit 2010 software (Hitachi, San Francisco, CA, USA) and Microsoft® Excel (v 2007). 
The calculated amounts of CYP2E1 were expressed in pmol/mg microsomal protein. 
The antibodies were stored and handled following manufacturer’s recommendations in order to 
guarantee optimal stability. The primary antibody was stored in small aliquots at -80°C in order to 
avoid repeated freeze-thawing. The reconstitution solution of the secondary antibody contained 
glycerol in order to prolong long term stability at -20°C. During the experiments, all solutions were 
stored on ice.  
2.4. Method validation 
Assay sensitivity, calibration model, linearity of dilution, spiking recovery, working range, intra and 
inter assay variability and precision, and cross-reactivity were evaluated prior to analysis of study 
samples.  
For the evaluation of the calibration model, a curve was fitted for each of six independent assay runs. 
The suitability of the model was evaluated by analysis of the relative error (%RE) of the back-
calculated calibration points within each run (%RE = 100 x (calculated concentration - nominal 
concentration)/nominal concentration). The %RE should be ≤20% (≤25% at LLOQ) for ≥75% of the 
calibrators within a curve. Furthermore, the mean %RE and mean %CV calculated from all runs (n=6) 
should both be ≤15% for each calibrator, except at the LLOQ where both should be ≤20% [9].   
The mean response of 10 blank samples plus 3 standard deviations was calculated to determine the 
assay sensitivity. The concentration corresponding with this response was defined as the lowest 
concentration that could be distinguished from a blank sample, and was used as the lower limit of 
the working range. The upper limit of the working range was defined based on literature information 
(based on naturally occurring CYP2E1 abundance in microsomes) and tested to comply with 
validation criteria. Linearity of dilution was evaluated by diluting a sample with a known 
concentration (500 pmol CYP2E1/mg protein) above the upper limit of the working range 1:3, 1:4 and 
1:6. The recovery (%) of the observed concentration to the expected concentration should be within 
the 85-115% interval. A spiking recovery experiment was used to assess matrix effects. Hereto, 
samples were prepared at five concentration levels in both dilution buffer (carbonate-bicarbonate, 
pH 9.4) and in blank matrix (blank supersomes, final protein concentration of 10 µg/ml). The 
recovery (%) of the observed concentration to the nominal concentration was calculated and 
evaluated against the 85-115% interval in both matrices. 
Intra assay and inter assay precision and accuracy were also evaluated according to the 
recommendations of and the statistical methods described by DeSilva et al [9]. The formulas used to 
perform this evaluation can be found at the end of the publication by De Silva et al. Validation 
samples were prepared in the sample matrix at five concentration levels: anticipated LLOQ, less than 
3 times LLOQ, medium, high and anticipated upper limit of the working range. Three independent 
determinations were done each run, for a minimum of 6 runs. The intra assay precision was 
estimated by the coefficient of variation, obtained after dividing the pooled intrabatch standard 
deviation of measured concentration values from the calculated run means with the sample nominal 
concentration. The standard deviation needed for the calculation of the %CV for the inter assay 
precision was calculated by the method of analysis of variance (ANOVA). Method accuracy (%RE) was 
determined by the percent deviation of the weighted sample mean from the sample nominal 
concentration. The target limits were an intra assay and inter assay precision (%CV) and absolute 
value of the mean bias (%RE) ≤ 20% (25% at LLOQ). In addition, the total error of the method (= sum 
of %CV and absolute value of the %RE) should be ≤ 30% (40% at LLOQ).  
Possible cross-reactivity with the most abundant CYP isoforms in liver microsomes was evaluated in 2 
of the validation runs. In the first run, a mix of recombinantly expressed CYP1A2, CYP2C8, CYP2C9, 
CYP2C19, CYP2D6, and CYP3A4 (“Supermix”) was added at 4 concentration levels (zero - low – 
intermediate – high) to a sample with a fixed concentration of CYP2E1. In order to cover the 
complete range of known important and abundant CYPs, cross-reactivity with recombinant CYP2A6 
and CYP2B6 (Corning® Supersomes™, Corning BV Life Sciences EMEA, Amsterdam, The Netherlands) 
was assessed in the second run. CYP2A6 was added at 4 concentration levels (zero - low – 
intermediate (and physiologically expected) – high), whereas CYP2B6 was only added in a low and 
intermediate concentration, due to the high protein content of the supersomes and the consequent 
impossibility to prepare a sample with a protein concentration of 10 µg/ml. . The cross-reactivity was 
evaluated following MacFarlane et al [10], according to the equation: 
 [(observed concentration - control concentration)/ supplemented concentration] * 100, 
with observed concentration = calculated CYP2E1 concentration of the supplemented sample, 
control concentration = calculated CYP2E1 concentration of the sample with no other CYP isoform(s) 
added, and supplemented concentration = concentration of the  supplemented CYP(s). Additionally, 
the calculated mean concentrations were compared with one-way ANOVA (using Microsoft Excel® 
2007). 
During sample analysis, in-study validation was performed within each run through the measurement 
of two validation samples, each of 3 concentration levels (less than 3 times LLOQ, medium and high). 
In order to accept the run, these results should meet the 4:6:30 rule [9], i.e. 4 out of the 6 VS should 
have a total error below 30%, and the 2 samples not meeting this requirement should not be at the 
same concentration level. Furthermore, ≥75% of the calibration points should have a %RE of ≤ ±15%. 
2.5. Proof of concept: application of the method and CYP activity determination 
Liver tissue samples were taken from the explanted livers from children undergoing liver 
transplantation, after obtaining written informed consent from the parent(s), as approved by the 
Ethics Committee of Ghent University Hospital (B67020084281). Microsomes were prepared 
following the method of Wilson et al [5] and subsequently analyzed with the validated method. Total 
protein content was estimated with the method of Bradford et al [11], and the microsomal 
suspensions were diluted to a final protein concentration of 10 µg/ml in the plating buffer 
(carbonate-bicarbonate, pH 9.4). For each of the samples, two wells were loaded with 100 µl of the 
dilution, and the average concentration in those two wells was considered the actual concentration 
of the samples. 
Furthermore, CYP2E1 activity was determined through incubation of the microsomes with 
chlorzoxazone (CZ). The reaction was initiated by the addition of NADPH to the reaction mixture 
containing the microsomes, KCl, phosphate buffer and CZ. After 15 min, reactions were stopped 
using a mixture of formic acid, acetonitrile, and water (3:55:42 (v:v:v)), and the amount of hydroxy-
chlorzoxazone (HCZ) was quantified using UPLC-MS/MS [12].  
The relationship between the activity and abundance was evaluated graphically using locally 
weighted scatterplot smoothing (LOWESS). Moreover, the Pearson’s correlation coefficient was 
calculated. All data analysis was performed using R® v.2.13 (R foundation for statistical computing, 
Vienna, Austria).  
3. Results and discussion 
Quantification of a specific CYP isoform in microsomes requires recombinant CYP enzymes (rCYP) for 
the preparation of calibrators. The rCYP2E1 enzymes used in this protocol were expressed in a 
baculovirus/insect cell system. This expression system has a high yield of functional CYP enzymes 
[13]. Moreover, it is capable to perform post-translational modifications, such as phosphorylation or 
O-linked glycosylation [14]. The obtained microsomes containing the enzyme are preferred over the 
purified enzyme, as purified rCYPs have a different conformation compared to the enzyme 
embedded in the endoplasmatic membrane [15].  
The final protocol for the quantification of CYP2E1 in microsomes using indirect ELISA was obtained 
after the optimization of several parameters, such as primary and secondary antibody concentration, 
optimal amount of protein to load in each well, the choice of blocking buffer, incubation times and 
temperatures.  
3.1. Choice of primary and secondary antibody 
Cytochrome P450 enzymes are embedded in the membrane of the smooth endoplasmatic reticulum, 
and remain as such during the preparation of the microsomes. Upon adsorption of the antigen, i.e. 
the CYP enzyme, to the wall of the microplate, some parts will be available for interaction with the 
antibody. However, it is unpredictable which parts are exposed and thus available. Therefore, the use 
of a polyclonal antibody raised against the full length human protein would be favorable in order to 
increase the probability of antigen-antibody interaction.  
 
3.2. Optimization of the protocol 
Several parameters were optimized in order to achieve a background signal as low as possible, in 
combination with sufficient sensitivity. Previously published studies describe average concentrations 
of 50 pmol CYP2E1/mg protein, and a minimum amount of 11 pmol CYP2E1/mg protein [8]. Based on 
these observations, a sensitivity of about 5 pmol CYP2E1/mg protein was aimed for. As such, 
decreases of up to 50% in CYP2E1 abundance could still be detected.  
The method for the evaluation of the assay sensitivity, i.e. the analysis of 10 blank samples, followed 
by the calculation of the concentration corresponding to the mean response plus 3 standard 
deviations, was used in order to determine the optimal conditions. Those conditions leading to the 
highest sensitivity were eventually chosen for validation. An assay sensitivity of 4 pmol CYP2E1/mg 
protein was obtained , thus allowing the detection of large decreases in CYP2E1 abundance 
compared to healthy adult individuals. Comparison of the sensitivity with other published methods 
for the quantification of CYP2E1 is difficult, as often the method is described, but without the 
validation parameters. One study, published by Kornilayev et al [16], describes the method 
characteristics of the quantification of CYP2E1 tryptic peptides using both ELISA and western blot. 
The ELISA methods show comparable sensitivity to our method, whereas the sensitivity of the 
western blot method was 10 pmol CYP2E1/mg protein. The same issue arises when trying to 
compare the sensitivity of our method to previously published western blot methods: the validation 
parameters are seldom described. Moreover, due to the semi-quantitative nature of western blot 
methods, where often the amount of investigated protein is relatively expressed compared to a 
control sample or other sample, an absolute comparison of the sensitivity is difficult to perform.  
In order to determine the optimal assay conditions, , the most favorable concentrations of primary 
and secondary antibody were determined by a checkerboard titration experiment. Samples 
containing 3 concentrations of CYP2E1 (0, 5 and 100 pmol/mg protein) were analyzed using different 
combinations of primary antibody concentration (156, 312, 468, 625, 938, 1250 ng/ml) and 
secondary antibody concentration (50, 75, and 100 ng/ml, according to the manufacturers 
guidelines). The combination of 625 ng/ml of primary antibody, and 100 ng/ml of secondary antibody 
was further used. Furthermore, in order to increase sensitivity by decreasing the background signal, 
the antibodies (both primary and secondary) were diluted in Starting Block buffer, a commercially 
prepared buffer, instead of in a 2% BSA solution in the wash buffer (TBS with 0.05% Tween 20®, pH 
7.2). The dilution in the blocking buffer most likely decreased non-specific binding. The optimal 
amount of protein to load in each well was evaluated by comparing the signals after plating 0.5µg, 
1µg and 1.5µg protein per well. One µg protein was chosen above 0.5 µg and 1.5 µg, which resulted 
in insufficient sensitivity and higher background signal, respectively. The incubation times and 
temperatures of the antibodies were also optimized, aiming for optimal sensitivity. Two types of 
commercially available blocking buffers were compared in order to aim for minimal non-specific 
binding. The highest precision was obtained by using the Starting Block buffer. 
3.3. Validation 
3.3.1. Calibration model 
After the determination of the assay sensitivity as described above, the working range of the assay 
was selected based on previously determined (mean) concentrations of CYP2E1 in adults [8]. The 
lowest calibrator was determined to be 4 pmol CYP2E1/mg protein, the upper limit was chosen at 
256 pmol CYP2E1/mg protein. Consequently, very low abundances, corresponding with a 50% 
reduction of the lowest reported concentration, as well as rather high abundances can be measured.  
The calibration model was selected based on the %RE of the back-calculated concentrations. Due to 
the clear asymmetry (compared to a 4-parameter logistics function) of the curve, a 5-parameter 
logistics (5-PL) was suggested (see Figure 1). Evaluation of the mean %RE in back-calculated 
concentrations showed the necessity of a 1/x weighting factor, in order to obtain sufficient accuracy 
at the lower concentrations. This model, a 5-PL function with 1/x weighting factor, was validated 
based on six independent assay runs. All requirements of %RE and %CV were met (see Table 1).  
(Figure 1) 
(Table 1) 
3.3.2. Spike and recovery 
A clear influence of the matrix proteins on the response was demonstrated by the spiking recovery 
experiment. As depicted in Table 2, the samples of rCYP2E1 diluted in plating buffer showed a low 
recovery, outside the 85-115% limits. In contrast, the samples diluted in blank matrix, thus having a 
final protein content of 10µg/ml, showed a recovery within those limits. These results show that all 
calibrators and validation samples should be diluted in blank matrix, in order to have an equal final 
microsomal protein content in all samples (10 µg/ml). If this would not be done, and the calibrator 
samples would be diluted in a buffer without additional proteins, a low concentration in a sample 
would be severely overestimated, probably due to non-specific binding of the antibodies.  
(Table 2) 
3.3.3. Dilution experiment 
As CYP2E1 is a highly inducible enzyme, high amounts of CYP2E1 can be expected. Increasing the 
upper limit of the working range was not possible due to the total protein content of the calibrators, 
which could not exceed 10 µg/ml. Therefore, a dilution experiment was set up in order to define the 
approach for the determination of samples with a concentration above the upper limit of the 
working range (256 pmol CYP2E1/mg protein). The recoveries of the 3-fold, 4-fold, and 6-fold 
dilutions in blank matrix of a sample with a high CYP2E1 concentration are shown in Table 3. After 
multiplication of the observed concentration with the dilution factor, all samples were within the 85-
115% interval of the nominal concentration. Thus, dilution of samples with a concentration above the 
upper limit of quantification will provide reliable quantitative measurement results. 
(Table 3) 
3.3.4. Accuracy and precision 
The results of the accuracy and precision evaluation are depicted in Table 4. The intra and inter assay 
precisions determine the variability of the results for the same sample analyzed under repeatability 
conditions and the intermediate precision, respectively. The assay precision was evaluated at 5 
concentration levels in 6 independent assay runs, with n=3 within each run. The coefficient of 
variation did not exceed 20% (25% at the LLOQ) for the intra assay precision (6.3 – 15.2%RSD), as 
well as for the intermediate precision (11.3 – 21.0%RSD), except for the 50 pmol CYP2E1 sample, 
where a minor deviation of the limit was seen. The assay accuracy (expressed as the %RE) was 
determined using the same 6 assay runs. The absolute value of the mean bias did not exceed the 
limit of 20% (25% at the LLOQ), indicating a good accuracy. Moreover, the assay’s total error was 
below 27.2 % at all concentration levels.  
(Table 4) 
3.3.5. Cross reactivity 
The homology in amino acid sequence between CYP isoforms from the same family (>40%) or 
subfamily (>55%) may lead to cross-reactivity of the primary antibody. The selectivity of the primary 
antibody was tested through the addition of CYP isoforms (CYP2A6, CYP2B6, CYP1A2, CYP2C8, 
CYP2C9, CYP2C19, CYP2D6, and CYP3A4), selected based on their high abundance or high importance 
in drug metabolism [1]. Table 5 summarizes the results from the cross-reactivity experiments. The 
percentage of cross reactivity appears to be quite high at low supplemented concentrations of 
CYP2B6 (25%). The recovery, however, was within the 85-115% interval of the concentration of the 
non-supplemented CYP2E1 sample. At higher and physiologically more relevant concentration, much 
lower % cross-reactivity was calculated (13.5%). Consequently, cross-reactivity of the antibody with 
CYP2B6 was considered negligible. Moreover, the method showed sufficient selectivity toward the 
detection of CYP2E1 in the presence of other abundant CYP isoforms, as also shown in Table 5. 
(Table 5) 
3.4. Application of the method 
The validated method for the quantitative determination of CYP2E1 was applied for the analysis of 
samples from an ongoing PK study. Additionally, the CYP2E1 activity was determined through the 
evaluation of the chlorzoxazone hydroxylase activity. As depicted in Figure 2, a positive correlation 
was observed between the two variables after logarithmic transformation, which is also reflected in 
the Pearson’s correlation coefficient  of 0.371. This implies that the studied pharmacokinetic 
situation does not alter the protein on the posttranslational level (Figure 2). 
4. Conclusion 
This article describes the development and full validation of an indirect ELISA for the quantification of 
CYP2E1 in human liver microsomes in a concentration range of 4 and 256 pmol CYP2E1/mg 
microsomal protein. The method was proven to be accurate and precise. The spiking recovery 
experiment showed the importance of an equal concentration of total protein in all samples, 
validation samples and calibrators. The polyclonal antibody against the full length protein showed 
acceptable cross-reactivity with the other abundant CYP isoforms. Analysis of samples from a 
pharmacokinetic study showed the suitability of this ELISA in the quantification of CYP2E1. We 
conclude that a valuable alternative to Western blot analysis has been presented, appropriate for use 
in various fields of research, e.g. toxicology and pharmacokinetics. 
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Table 1: Validation of the calibration model: %RE of the back-calculated concentrations was ≤20% 
(≤25% at LLOQ) for ≥75% of the calibrators within each batch run. The mean %RE and %CV calculated 
from all runs (n=6) were both ≤15% for each calibrator (≤20% at LLOQ).  
 
Nominal concentration (pmol CYP2E1/mg protein) 
4.00 8.00 16.0 32.0 64.0 128 256 
Batch run % RE of the back-calculated concentrations 
1 -7.0 2.0 1.9 -3.0 1.7 -0.4 0.5 
2 -8.8 4.5 -5.3 4.6 -0.2 -1.2 0.4 
3 -10.0 8.3 -7.9 5.4 -2.9 1.0 0.8 
4 -5.8 -2.4 2.8 1.0 -0.9 0.5 -0.4 
5 -5.5 -2.8 -7.6 12.1 -3.8 -0.7 0.4 
6 0.8 10.4 2.6 -1.9 -3.2 2.0 -0.7 
        
Mean %RE -6.0 3.3 -2.2 3.0 -1.5 0.2 0.2 






Table 2: Spike-and-recovery experiment: samples diluted in plating buffer show poor recovery, all 












Diluted in blank 
matrix 
Diluted in plating 
buffer 
4 3.68 2.93 91.9 28.9 
10 11.6 10.1 116 66.4 
50 52.9 47.9 106 84.3 
100 101 90.0 101 90.3 
130 131 122 101 91.7 
 
Table 3: dilution of a sample with a concentration of CYP2E1 above the upper limit of quantification 
of 256 pmol CYP2E1/mg protein. 
Dilution factor (DF) Observed (pmol CYP2E1/mg protein) x DF 
Recovery 
% 
3 454 90.8 
4 447 89.3 





Table 4: Accuracy and precision evaluation 
 
  
Nominal concentration (pmol CYP2E1/mg protein) 
Characteristic Statistic 4.00 10.0 50.0 130 256 
# Results N 18 18 18 18 16 
Accuracy Mean bias (%RE) 0.9 8.9 6.0 4.7 -16.4 
Precision Intra assay(%CV) 15.2 6.3 7.0 6.4 6.8 
 
Inter assay (%CV) 19.7 16.5 21.0 11.3 9.8 
Total error       
(accuracy + 
precision) 
|Mean bias| + Inter 
assay 20.5 25.4 27.2 16.0 26.2 
Table 5: Cross-reactivity with CYP2A6, CYP2B6 and the BD Supermix®, containing human CYP1A2, 
CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Cross-reactivity was calculated as: 
[(observed concentration - control concentration)/ supplemented concentration] * 100, 
with observed concentration = calculated CYP2E1 concentration of the supplemented sample, 
control concentration = calculated CYP2E1 concentration of the sample with no other CYP isoform(s) 








(pmol/mg protein) (± SD) 
% cross 
reactivity % recovery 
Run 1 
    CYP2E1   52.7 ± 2.2     
Supermix 20 47.9 ± 2.4 -23.9 90.9 
 
50 47.6 ± 2.7 -10.1 90.4 
 
350 46.0 ± 3.1 -1.91 87.3 
     Run 2        
CYP2E1   53.1 ± 1.6     
CYP2A6 10 53.7 ± 2.5 5.39 101 
 
50 57.1 ± 4.8 7.96 107 
 
250 57.9 ± 2.0 1.91 109 
     CYP2B6 10 55.6 ± 2.3 25.0 105 
 
50 59.9 ± 4.2 13.5 113 
Figures 
Figure 1: Representative 5-PL calibration curve with 1/x weighting factor.  
 
Figure 2: Correlation of CYP2E1 abundance as determined by ELISA with the chlorzoxazone 
hydroxylase activity: protein levels were positively correlated with CZ-OH activity. 
 
 
